Gianfranco Nazzi – CEO, Almirall
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[4]
In 2016, it generated a total revenue of 859.3 million € [5] and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and the United States.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Esteve’s presence in Spain dates back to 1929, and has been a privileged witness to the evolution of modern Spain. In more recent times, the country’s crisis has changed the…
“We have to be optimistic, but we also need to plan much better for the future with regard to health authorities and medical education. I believe that industry in Spain…
“We have to be optimistic, but we also need to plan much better for the future with regard to health authorities and medical education. I believe that industry in Spain…
After serving as President of Lilly Spain between 2001 and 2009, Javier Ellena spent three years running Lilly’s middle-sized European markets (EMS). In 2012, he returned to his previous role…
After serving as President of Lilly Spain between 2001 and 2009, Javier Ellena spent three years running Lilly’s middle-sized European markets (EMS). In 2012, he returned to his previous role…
“While the last five years of economic struggle and brain drain have been some of the most calamitous times for the country, I maintain a strong sense of optimism. Spain…
Spain’s pharmaceutical industry has been subject to numerous austerity measures over the past few years as a consequence of the country’s recession. Humberto Arnés, director general of Spain’s research-based pharmaceutical…
The Spanish pharmaceutical industry has been affected by a number of austerity measures in recent years, and companies selling generics in Spain have encountered various challenges and opportunities as a…
See our Cookie Privacy Policy Here
